ブルガダ症候群の市場規模、シェア、成長分析、診断別、薬剤別、治療別、エンドユーザー別、地域別 - 産業予測、2025-2032年

ブルガダ症候群の世界市場規模は2023年に14億米ドルと評価され、2024年の14億8,000万米ドルから2032年には23億1,000万米ドルに成長し、予測期間中（2025-2032年）にCAGR 5.7％で成長する見通しです。

世界のブルガダ症候群市場は、心臓の電気系統を混乱させるこの稀な遺伝性疾患の有病率が上昇しているため、心血管健康において大きな変革が起きています。認知度の向上は、遺伝子検査技術の進歩や個別化医療の重視の高まりに後押しされ、より良い診断と治療戦略を後押ししています。このような前向きな変化にもかかわらず、早期発見と本症の複雑さの理解における課題は依然として残っており、現在進行中の研究イニシアチブを促しています。競争環境の特徴は、製薬会社、診断研究所、医療機器メーカー間の協力であり、いずれもブルガダ症候群の管理において満たされていないニーズに応えようと努めています。全体として、利害関係者が協力して患者の転帰を改善し、治療の選択肢を広げるために、この市場は有望です。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

ブルガダ症候群市場規模：診断別

• 市場概要
• 心電図
• 電気生理学（Ep）検査
• 遺伝子検査

ブルガダ症候群市場規模：薬物別

• 市場概要
• 抗不整脈薬
• 向精神薬
• 麻酔薬/鎮痛薬
• その他

ブルガダ症候群市場規模：治療別

• 市場概要
• 植込み型除細動器
• 薬物療法

ブルガダ症候群市場規模：エンドユーザー別

• 市場概要
• 病院
• クリニック
• 診断センター
• その他

ブルガダ症候群市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Boston Scientific Corporation（USA）
• LivaNova plc（UK）
• Medtronic（USA）
• Abbott（USA）
• Edwards Lifesciences Corporation（USA）
• Novartis AG（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• MRI Interventions（USA）
• HeartSine Technologies LLC（USA）
• GeneDx（USA）
• PGxHealth LLC（USA）
• GE Healthcare（UK）
• Pfizer, Inc（USA）
• GlaxoSmithKline（UK）
• Eli Lilly Company（USA）
• Taj Pharmaceuticals Ltd（India）
• Biotronik SE & Co. KG（Germany）
• MicroPort Scientific Corporation（China）
• St. Jude Medical, Inc.（USA）
• Conmed Corporation（USA）

結論と推奨事項

Global Brugada Syndrome Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.48 billion in 2024 to USD 2.31 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The global Brugada syndrome market is experiencing significant transformation within cardiovascular health due to the rising prevalence of this rare genetic disorder that disrupts the heart's electrical system. Enhanced awareness is driving better diagnosis and treatment strategies, bolstered by advancements in genetic testing technologies and an increasing emphasis on personalized medicine. Despite these positive shifts, challenges in early detection and comprehension of the syndrome's intricacies persist, prompting ongoing research initiatives. The competitive landscape is marked by collaboration among pharmaceutical companies, diagnostic labs, and medical device manufacturers, all striving to meet the unmet needs in managing Brugada syndrome. Overall, the market shows promise as stakeholders work together to improve patient outcomes and expand treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Brugada Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Brugada Syndrome Market Segmental Analysis

Global Brugada Syndrome Market is segmented by Diagnosis, Drugs, Treatment, End user and region. Based on Diagnosis, the market is segmented into Electrocardiogram, Electrophysiology (Ep) Test and Genetic Testing. Based on Drugs, the market is segmented into Antiarrhythmic drugs, Psychotropic drugs, Anesthetics/analgesics and Others. Based on Treatment, the market is segmented into Implantable Cardioverter-Defibrillator and Drug Therapy. Based on End user, the market is segmented into Hospitals, Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Brugada Syndrome Market

The Brugada Syndrome market is significantly driven by the growing awareness and comprehension of the condition among both healthcare providers and the general public. As knowledge about Brugada syndrome expands, it leads to earlier diagnosis and timely intervention, which ultimately enhances patient outcomes. This collective understanding encourages medical professionals to recognize the symptoms more effectively and promotes education initiatives aimed at informing the public. Consequently, such advancements not only improve the rate of detection but also empower patients with knowledge about their condition, fostering a more proactive approach to management and treatment in the expanding Brugada syndrome market.

Restraints in the Global Brugada Syndrome Market

A significant constraint in the global Brugada Syndrome market is the insufficient understanding of its underlying mechanisms. This complex genetic disorder presents challenges in achieving accurate diagnoses and developing targeted treatment options. The lack of comprehensive knowledge hampers advancements in research and impedes effective strategies for managing the condition. As a result, healthcare professionals may struggle to identify the syndrome promptly or to provide the most appropriate therapies, ultimately limiting market growth and innovation in this area. Overcoming this limitation is crucial for improving patient outcomes and advancing the overall understanding of Brugada Syndrome.

Market Trends of the Global Brugada Syndrome Market

The Global Brugada Syndrome market is witnessing a notable trend towards the rising emphasis on genetic testing, fueled by an enhanced understanding of the genetic underpinnings of the condition. Advances in genomic technologies have paved the way for more precise and accessible genetic analyses that identify mutations linked to Brugada syndrome. Concurrently, the integration of artificial intelligence (AI) in electrocardiogram (ECG) analysis is transforming diagnosis, enabling automated detection of subtle cardiac abnormalities that may otherwise go unnoticed. This confluence of genetic insights and technological innovations is poised to improve patient outcomes and drive continued growth in the Brugada Syndrome market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Brugada Syndrome Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Electrocardiogram
• Electrophysiology (Ep) Test
• Genetic Testing

Global Brugada Syndrome Market Size by Drugs & CAGR (2025-2032)

• Market Overview
• Antiarrhythmic drugs
• Psychotropic drugs
• Anesthetics/Analgesics
• Others

Global Brugada Syndrome Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Implantable Cardioverter-Defibrillator
• Drug Therapy

Global Brugada Syndrome Market Size by End user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Diagnostic Centers
• Others

Global Brugada Syndrome Market Size & CAGR (2025-2032)

• North America (Diagnosis, Drugs, Treatment, End user)
  • US
  • Canada
• Europe (Diagnosis, Drugs, Treatment, End user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Drugs, Treatment, End user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Drugs, Treatment, End user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Drugs, Treatment, End user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LivaNova plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Edwards Lifesciences Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MRI Interventions (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HeartSine Technologies LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneDx (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PGxHealth LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taj Pharmaceuticals Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotronik SE & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort Scientific Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• St. Jude Medical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Conmed Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations